A5057622557- Monoclonal and Polyclonal Antibodies Research
- Advanced biosensing and bioanalysis techniques
- Nanoplatforms for cancer theranostics
- 3D Printing in Biomedical Research
- Nanoparticle-Based Drug Delivery
- Mosquito-borne diseases and control
- Gold and Silver Nanoparticles Synthesis and Applications
- Electrospun Nanofibers in Biomedical Applications
- Hydrogels: synthesis, properties, applications
- Polymer Surface Interaction Studies
- Cancer Cells and Metastasis
- CAR-T cell therapy research
- Glycosylation and Glycoproteins Research
- Wound Healing and Treatments
- Virus-based gene therapy research
- Photodynamic Therapy Research Studies
- Biosensors and Analytical Detection
- Gut microbiota and health
- Periodontal Regeneration and Treatments
- biodegradable polymer synthesis and properties
- Bone Tissue Engineering Materials
- Receptor Mechanisms and Signaling
- Silk-based biomaterials and applications
- Tuberculosis Research and Epidemiology
- Piperaceae Chemical and Biological Studies
Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco
2017-2025
Secretaría de Salud de Jalisco
2018-2025
Consejo Nacional de Humanidades, Ciencias y Tecnologías
2018-2023
Pharmaceutical Biotechnology (Czechia)
2018-2022
Centro de Investigación y Proyectos en Ambiente y Desarrollo
2019
Center for Scientific Research and Higher Education at Ensenada
2013-2018
Universidad Autónoma de Baja California
2013
Institute of Marine Biotechnology
2013
Istituto di Scienze Marine del Consiglio Nazionale delle Ricerche
2013
Surface-enhanced Raman spectroscopy (SERS) has recently emerged as an innovative tool for therapeutic-drug monitoring (TDM), making it ideal candidate personalized treatment. Herein, we report a layer-by-layer (LbL) approach the fabrication of highly reproducible hybrid SERS substrate based on graphene oxide (GO)-supported l-cysteine-functionalized starlike gold nanoparticles (SAuNPs). These designed substrates were utilized TDM paclitaxel and cyclophosphamide in blood serum. The SAuNPs'...
Retaining the hemocompatibility, supporting cell growth, and exhibiting anti-inflammatory antioxidant properties, while having antimicrobial activity, particularly against multidrug-resistant bacteria (MDR), remain a challenge when designing aerogels for biomedical applications. Here, we report that our synthesized alginate-based containing either 7.5 or 11.25 μg of lipoic acid-capped silver nanoparticles (AgNPs) showed improved hemocompatibility properties retaining their effect MDR...
Ligand-targeted multifunctional nanoliposome combining NaYF<sub>4</sub>:Yb,Er nanoparticles for NIR-activated bioimaging and chemo-photodynamic therapy against HER2 positive breast cancer.
Glioblastoma is the most common and highly malignant brain tumor in adults. New targeted therapeutic approaches are imperative. EGFRvIII has appealing targets using monoclonal antibodies. Thus, endeavors toward developing new mAbs therapies for GBM capable of targeting biomarker must prevail to improve patient’s prognosis. Here, we isolated characterized an anti-EGFRvIII vNAR from a non-immune freshwater stingray mixed library, termed R426. The R426 pEGFRvIII interaction was demonstrated by...
Glioblastoma (GBM) is a highly aggressive and malignant brain tumor, characterized by hypoxia in its microenvironment, which drives growth resistance to treatments. Hypoxia-inducible factor 1 (HIF-1) plays central role GBM progression regulating cellular adaptation low oxygen availability, promoting processes such as angiogenesis cell invasion. However, studying modeling under hypoxic conditions complex, especially due the limitations of animal models. In this study, we developed glioma...
The UCNPs-ZnPc-Trastuzumab nanocomplex tracks and kills HER2-positive breast cancer cells upon NIR-excitation.
The therapeutic use of single domain antibodies (sdAbs) is a promising new approach because these small maintain antigen recognition and neutralization capacity, have thermal chemical stability good solubility. In this study, using phage display technology, we isolated variable IgNAR (vNAR) from Heterodontus francisci shark immunized against the recombinant human cytokine TNFα (rhTNFα). One clone T43, which expresses vNAR protein in periplasmic space, was fourth round panning. T43 had...
Abstract Immunotherapies based on antibody fragments have been developed and applied to human diseases, describing novel formats. The vNAR domains a potential therapeutic use related their unique properties. This work used non-immunized Heterodontus francisci shark library obtain with recognition of TGF-β isoforms. isolated T1 selected by phage display demonstrated binding the isoforms (-β1, -β2, -β3) direct ELISA assay. These results are supported using for first time Single-Cycle kinetics...
Abstract Background In sepsis, tumor necrosis factor (TNF) is the key triggering respiratory burst, tissue injury and disseminated coagulation. Anti-TNF strategies based on monoclonal antibodies or F(ab’) 2 fragments have been used in sepsis with contradictory results. Immunoglobulin new antigen receptors (IgNAR) are a unique subset of consisting five constant ( C NAR) one variable domains V NAR). NAR smallest, naturally occurring, antibody-based immune recognition units, having potential...
Variable new antigen receptor domain (vNAR) antibodies are novel, naturally occurring that can be isolated from naïve, immune or synthetic shark libraries. These molecules very interesting to the biotechnology and pharmaceutical industries because of their unique characteristics related size tissue penetrability. There have been some approved anti-angiogenic therapies for ophthalmic conditions, not vNAR. This includes biologics chimeric proteins neutralize vascular endothelial growth factor...
Glioblastoma is the most prevalent and fatal form of primary brain tumors. New targeted therapeutic strategies for this type tumor are imperative given dire prognosis glioblastoma patients poor results current multimodal therapy. Previously reported drawbacks antibody-based therapeutics include inability to translocate across blood–brain barrier reach intracellular targets due their molecular weight. These disadvantages translate into target neutralization cancer maintenance. Unlike...
Mycobacterium tuberculosis and M. smegmatis form drug-tolerant biofilms through dedicated genetic programs. In support of a stepwise process regulating biofilm production in mycobacteria, it was shown elsewhere that lsr2 participates intercellular aggregation, while groEL1 required for maturation smegmatis. Here, by means RNA-Seq, we monitored the early steps bovis BCG, to distinguish aggregation from attachment surface. Genes encoding transcriptional regulators dosR BCG0114 (Rv0081) were...
Epidermal growth factor receptor 2 (HER2) is the second target molecule most commonly used in breast cancer treatment. Both recurrence and metastasis are still deadly for HER2+ patients. Hydrogels can be an option developing three-dimensional (3D) cell culture systems that resemble tumor features better than monolayer cultures could preclinical screening new biotherapeutics. Biopolymers (gelatin alginate) were to develop a hydrogel capable of encapsulating living cells BT-474/GFP. The was...
<italic>N</italic>-Acetylcysteine promotes tissue regeneration. It also shows anticoagulant properties. We modified <italic>N</italic>-acetylcysteine-containing hydrogels to improve wound healing without hindering blood-clotting.
Glioblastoma (GBM), the most frequent type of brain tumour in adults, is highly aggressive and invasive. No curative treatment currently available for GBM; patient survival estimated at 15 months from diagnosis. Little progress has been made conventional over 20 years; this largely due to aggressiveness localisation limited availability systemic drugs that can penetrate blood–brain barrier. In search new treatments GBM, showing promising results preclinical studies frequently fail phase I II...